Document is current
Any future updates will be listed below
-
Authors
Simpson, Rebecca C.
Shanahan, Erin R.
Batten, Marcel https://orcid.org/0000-0002-3726-3790
Reijers, Irene L. M.
Read, Mark https://orcid.org/0000-0002-1481-4780
Silva, Ines P.
Versluis, Judith M.
Ribeiro, Rosilene
Angelatos, Alexandra S.
Tan, Jian
Adhikari, Chandra
Menzies, Alexander M.
Saw, Robyn P. M. https://orcid.org/0000-0002-3354-806X
Gonzalez, Maria
Shannon, Kerwin F. https://orcid.org/0000-0001-8538-3132
Spillane, Andrew J.
Velickovic, Rebecca
Lazar, Alexander J. https://orcid.org/0000-0002-6395-4499
Damania, Ashish V.
Mishra, Aditya K.
Chelvanambi, Manoj https://orcid.org/0000-0003-2130-3118
Banerjee, Anik
Ajami, Nadim J.
Wargo, Jennifer A. https://orcid.org/0000-0003-3438-7576
Macia, Laurence https://orcid.org/0000-0003-0835-851X
Holmes, Andrew J.
Wilmott, James S.
Blank, Christian U. https://orcid.org/0000-0002-7945-5846
Scolyer, Richard A. https://orcid.org/0000-0002-8991-0013
Long, Georgina V. https://orcid.org/0000-0001-8894-3545
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council
University of Sydney | Sydney Medical School | Sydney Medical School Foundation
University of Sydney à Beckett Cancer Research Trust Tour de Cure Australia
Tour de Cure
- License Information
-
More Information
Article History
Received: 3 May 2022
Accepted: 22 July 2022
First Online: 22 September 2022
Competing interests
: A.M.M has received fees for advisory board membership from BMS, MSD, Novartis, Roche, Pierre Fabre and Qbiotics. R.P.M.S. has received honoraria for advisory board participation from MSD, Novartis and Qbiotics, and speaking honoraria from BMS and Novartis. A.J.S has received fees for professional services from Eli Lily Australia. G.V.L. is a consultant advisor for Agenus, Amgen, Array Biopharma, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Evaxion Biotec, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., Innovent Biologics USA, Merck Sharpe and Dohme, Novartis, OncoSec, PHMR Limited, Pierre Fabre, Provectus, Qbiotics and Regeneron. R.A.S has fees for professional services from Roche, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp and Dohme, NeraCare, AMGEN, Bristol-Myers Squibb, Myriad Genetics and GlaxoSmithKline. All compensation was provided for work completed outside of the current work. The remaining authors declare no competing interests.
